Safety of Cardioversion of Acute Atrial Fibrillation

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

7700 participants

Study Classification

OBSERVATIONAL

Study Start Date

2011-06-30

Study Completion Date

2012-06-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of this study is to investigate the complications of cardioversion of acute (\<48 hours duration) atrial fibrillation (AF).

Primary Outcome Measures:

\- Incidence and predictors of thromboembolic complications, especially stroke, and death \<31 days after cardioversion of acute AF

Secondary Outcome Measures:

* Number of therapy non-responder and early recurrence of AF
* Bleeding complications during the 31 days follow-up
* Hemodynamic complications of cardioversion

Estimated Enrollment: 3000 cases

Study Start Date: Jun 2011

Estimated Study Completion Date: December 2011

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

FINnish CardioVersion Study II

NCT02850679

Atrial Fibrillation

COMPLETED

Role of Subsequent Atrial Tachycardia in Mechanisms of Persistent AF

NCT01896570

Atrial Fibrillation

COMPLETED

Catheter Ablation of All Inducible AT Post AF Ablation

NCT03343860

Atrial Tachycardia Atrial Fibrillation

COMPLETED NA

Atrial Fibrillation Screening Post Ischemic Cerebrovascular Events

NCT05134454

Ischemic Stroke TIA

RECRUITING NA

CArdioversion of Short Duration Atrial Fibrillation

NCT02112318

Atrial Fibrillation Electrocardiography Electrical Remodeling

TERMINATED

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

It has been a common practice to perform cardioversion of acute (\<48 hour) AF without any anticoagulation. The new European guidelines recommend that anticoagulation should be started already before cardioversion in all patients with CHADS2VASC score indicating need for long-term oral anticoagulation. The evidence behind these guidelines is, however, scarce. In this retrospective study we collect data on the safety of acute AF cardioversion from emergency rooms of two university hospitals and one secondary referral center from the years 2003-2010.

Inclusion criteria:

All patients admitted to emergency room because of acute AF in whom electrical or pharmacological cardioversion was attempted \<48 from the beginning of the symptoms.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Atrial Fibrillation

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

RETROSPECTIVE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* patients admitted to emergency room because of acute AF in whom electrical or pharmacological cardioversion was attempted \<48 from the beginning of the symptoms